Semaglutide vs Retatrutide
Semaglutide and Retatrutide represent two generations of incretin-based peptide research. Semaglutide is an established GLP-1 receptor agonist with extensive clinical data and FDA approval. Retatrutide is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously — making it the first 'triagonist' in advanced clinical development.
Phase II trial data for Retatrutide showed unprecedented weight reduction (~24% at 48 weeks), generating significant research interest. However, it's still in clinical development with less published data than semaglutide.
Similarities
- =Both activate GLP-1 receptors as part of their mechanism
- =Both are administered via subcutaneous injection
- =Both show significant effects on body weight and metabolic markers
- =Both are being developed/marketed by Eli Lilly (retatrutide) and Novo Nordisk (semaglutide)
- =Both carry GI side effect profiles typical of incretin-based therapies
- =Both are available as research peptides from select vendors
Key Differences
| Aspect | Semaglutide | Retatrutide |
|---|---|---|
| Receptor Targets | GLP-1 receptor only | Triple agonist: GLP-1 + GIP + Glucagon receptors |
| Weight Loss (Trials) | ~15-17% (STEP trials, approved dose) | ~24% at highest dose (Phase II, 48 weeks) |
| FDA Status | Approved (Ozempic/Wegovy) | Phase III clinical trials (not yet approved) |
| Glucagon Activity | None | Glucagon receptor agonism — increases energy expenditure |
| Research Maturity | Thousands of published studies, extensive real-world data | Phase II data published; Phase III ongoing |
| Vendor Availability | Widely available from research vendors | Limited availability — newer compound, fewer vendors stock it |
| Cost | Competitively priced across many vendors | Premium pricing due to novelty and limited supply |
Which to Choose for Your Research
Well-characterized metabolic research
SemaglutideSemaglutide has the deepest evidence base of any GLP-1 RA, with completed Phase III programs for diabetes, obesity, cardiovascular outcomes, kidney disease, and NASH/MASH.
Triple incretin signaling research
RetatrutideRetatrutide is the only triagonist in advanced development. For researchers studying the interplay of GLP-1, GIP, and glucagon signaling, it's a unique tool.
Maximum weight reduction research
RetatrutidePhase II data shows ~24% body weight reduction — the highest of any single agent in clinical trials to date. The glucagon receptor component may increase energy expenditure beyond what GLP-1 alone achieves.
Cardiovascular outcome research
SemaglutideSemaglutide has completed cardiovascular outcome trials (SELECT) showing 20% MACE reduction. Retatrutide has no cardiovascular outcome data yet.
Budget-conscious research
SemaglutideSemaglutide is more widely available and competitively priced. Retatrutide carries a premium due to novelty and limited vendor supply.
The Verdict
Semaglutide is the established standard with unmatched clinical evidence. Retatrutide is the most exciting emerging compound in metabolic research, with Phase II data suggesting potentially superior weight reduction due to its unique triple-agonist mechanism. For most research applications today, semaglutide offers the stronger foundation. For researchers on the cutting edge of incretin biology, retatrutide represents the next frontier.
Retatrutide's vendor availability is limited and pricing is premium. Semaglutide remains the more accessible and cost-effective research tool.
Frequently Asked Questions
Is retatrutide more effective than semaglutide?
Phase II trial data suggests retatrutide may produce greater weight reduction (~24% vs ~15-17%), likely due to its additional glucagon receptor activity increasing energy expenditure. However, this is Phase II data — Phase III results will provide definitive comparison.
When will retatrutide be FDA-approved?
Retatrutide is currently in Phase III clinical trials (as of early 2026). FDA approval, if granted, would likely come in 2027 at the earliest. It remains a research compound for now.
What does the glucagon component add?
Glucagon receptor activation increases hepatic energy expenditure and fat oxidation. This may explain retatrutide's greater weight reduction — it both reduces food intake (GLP-1/GIP) and increases calorie burning (glucagon). This dual approach is novel.
Can I find retatrutide from research vendors?
Retatrutide is available from select research vendors but supply is more limited than semaglutide. Pricing is typically higher. Check our vendor pages for current availability.
Semaglutide
View full compound page with vendor pricing.
Compare 31 products →Retatrutide
View full compound page with vendor pricing.
Compare 16 products →More Comparisons
For research reference only. Not medical advice. Not for human consumption. All compounds discussed are research chemicals.